Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Severe asthma Type 2-low is a phenotype of severe asthma characterized by limited Type 2 inflammatory biomarkers. According to Porpodis et al. (2025), T2-low asthma accounted for 20.1% of 602 adults with severe asthma enrolled across the PHOLLOW study. The findings indicate a substantial burden of uncontrolled asthma among affected patients. According to the severe asthma type 2-low epidemiology forecast by Expert Market Research, the condition is expected to remain an important severe-asthma phenotype.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Severe Asthma Type 2-Low Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of severe asthma type 2-low. It projects the future incidence and prevalence rates of severe asthma type 2-low cases across various populations. The study covers age, gender, and type as major determinants of the severe asthma type 2-low population. The report highlights patterns in the prevalence of severe asthma type 2-low over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of severe asthma type 2-low in the 8 major markets.
Regions Covered
Severe asthma type 2-low is a difficult-to-treat form of asthma in which airway inflammation occurs without the prominent eosinophilic, allergic, or interleukin-driven signature of type 2 disease. It is not transmitted between people and has no single causative organism; it arises from chronic airway inflammation shaped by environmental exposures such as smoking and ozone, as well as comorbid obesity. Recognized subtypes include neutrophilic and paucigranulocytic asthma, and low-inflammatory forms, which are often associated with corticosteroid insensitivity and persistent symptoms. Because biomarker cutoffs vary, identifying T2-low endotype patients remains challenging in routine clinical practice.
|
Parameter |
Insight |
|
Largest Patient Pool |
United States |
|
Fastest Growing Country |
India |
|
High-Risk Population |
Smokers, individuals with obesity, and older adults |
|
Key Diagnostic Method |
Spirometry |
|
Major Risk Factor |
Tobacco smoke exposure |
|
Major gap in the market |
Underdiagnosis and limited phenotyping of type 2-low severe asthma |
The severe asthma type 2-low epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the severe asthma type 2-low epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for severe asthma type 2-low and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
Type 2-low asthma represented 20.1% of 602 adults with severe asthma in the PHOLLOW study. Among patients with severe uncontrolled asthma, prevalence ranged from 18% to 39% based on different biomarker thresholds, as reported by Konstantinos Porpodis et al., 2025, and Arja Viinanen et al., 2023. |
|
Gender-Specific Cases of the Disease |
As per Yueh-Ying Han et al., 2025, type 2-low asthma in children was associated with a higher likelihood of being female compared with controls. Gender-related differences may contribute to variation in the epidemiological distribution of Type 2-low asthma across patient populations. |
|
Age-Specific Cases of the Disease |
According to Yueh-Ying Han et al., 2025, 231 of 505 children (45.7%) with asthma had Type 2-low asthma. The type 2-low group was also more likely to be older than controls, indicating variation in phenotype distribution across age groups. |
|
Ethnicity-Wise Cases of the Disease |
Ethnic and demographic characteristics can contribute to variation in asthma phenotype distribution through differences in environmental exposures, socioeconomic conditions, and underlying population characteristics. Yueh-Ying Han et al., 2025, reported racial and ethnic differences across asthma subtypes in children. |
|
Mortality and Survival Analysis of the Disease |
The epidemiological burden of type 2-low severe asthma is reflected by disease control and exacerbation patterns. According to Konstantinos Porpodis et al., 2025, 71.1% of type 2-low patients experienced at least one clinically significant exacerbation during the preceding year. |
|
Disease Type |
Prevalence |
|
Neutrophilic Type 2-Low Asthma |
Accounts for a major share of the recognized type 2-low inflammatory phenotypes and is characterized by neutrophilic airway inflammation. Smoking, air pollution, infections, obesity, and other environmental exposures can contribute to its development and persistence. |
|
Paucigranulocytic Type 2-Low Asthma |
Represents another major subtype of type 2-low asthma and is characterized by limited eosinophilic and neutrophilic airway inflammation. Airway hyperresponsiveness, structural airway changes, and non-inflammatory mechanisms may contribute to disease persistence. |
|
Obesity-Related Type 2-Low Asthma |
Represents an important clinical subtype, particularly among patients with excess body weight and metabolic dysfunction. |
|
Others |
Other type 2-low presentations include late-onset, aging-related, exposure-related, infection-associated, and airway-remodeling phenotypes, which contribute to the heterogeneity of the disease. |

Read more about this report - Request a Free Sample
The severe asthma type 2-low epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
Obesity-related Type 2-low asthma is an important clinical pattern in the pediatric population. According to Yueh-Ying Han et al., 2025, children with type 2-low asthma were more likely to be older, female, and overweight or obese. Current second-hand smoke exposure was also associated with Type 2-low asthma, supporting the relevance of metabolic and environmental factors in its epidemiological distribution. |
|
Germany |
Type 2-low severe asthma can be differentiated through low type 2 inflammatory biomarker profiles, particularly low blood eosinophil counts and fractional exhaled nitric oxide. Factors affecting identification include biomarker variability, corticosteroid exposure, and differences in the thresholds used to classify type 2-low asthma. |
|
France |
The epidemiological identification of type 2-low severe asthma in France is influenced by biomarker-defined phenotyping, particularly blood eosinophil and fractional exhaled nitric oxide levels. Variation in biomarker thresholds and repeated measurements can affect the identification and reported distribution of type 2-low asthma. |
|
Italy |
Type 2-low severe asthma in Italy is characterized epidemiologically through low type 2 inflammatory biomarker profiles. Its identification can be influenced by variation in blood eosinophil and fractional exhaled nitric oxide measurements and by the classification thresholds applied when distinguishing type 2-low from other severe asthma phenotypes. |
|
Spain |
Low-biomarker Type 2-low asthma in Spain is relevant to severe asthma phenotyping. Factors influencing its identification include blood eosinophil and fractional exhaled nitric oxide measurements, biomarker stability over time, and exposure to corticosteroid treatment, which may influence observed inflammatory biomarker levels. |
|
United Kingdom |
Non-eosinophilic/low-blood-eosinophil type 2-low asthma represents an important phenotype among patients with uncontrolled severe asthma. According to Bo Ding et al., 2024, 72.9% of patients with uncontrolled severe asthma had low blood eosinophil levels. The analysis also highlighted variability in eosinophil levels and possible suppression associated with corticosteroid exposure. |
|
Japan |
The available evidence supports assessment of type 2-low asthma within the broader severe asthma population through biomarker-based phenotyping. According to Toshiyuki Koya et al., 2023, severe asthma accounts for 2.4%–12.7% of asthma cases in Japan, providing an established population in which different severe asthma phenotypes can be evaluated. |
|
India |
Type 2-low severe asthma is an established phenotype within India's heterogeneous severe asthma population. According to Deepak Talwar et al., 2022, 15% of 100 adults with severe asthma had the type 2-low phenotype, characterized by low absolute eosinophil count and immunoglobulin E levels and absence of allergic symptoms. |
A major gap in severe asthma type 2-low disease management is the limited availability of validated biomarkers and standardized approaches for identifying non-type 2 inflammatory phenotypes. This can contribute to delayed phenotyping and treatment optimization, particularly in patients who remain uncontrolled despite conventional inhaled therapies. An important opportunity exists for improved diagnostic approaches incorporating inflammatory profiling, lung-function assessment, and clinical characteristics. Across the United States, Europe, Japan, and India, growing recognition of severe asthma heterogeneity may support demand for more personalized management strategies and the development of therapies targeting non-type 2 inflammatory pathways.
Severe asthma type 2-low treatment focuses on achieving symptom control, reducing exacerbations, and improving lung function through optimized inhaled therapy and management of contributing factors. High-dose inhaled corticosteroids combined with long-acting beta2-agonists remain a foundation of treatment, although corticosteroid responsiveness may be limited in some type 2-low patients. Additional options include long-acting muscarinic antagonists, leukotriene receptor antagonists, and, when clinically appropriate, maintenance oral corticosteroids. Bronchodilator therapy and non-pharmacological measures, including smoking cessation, weight management, vaccination, and management of comorbidities, may support disease control.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.